Novo Nordisk says Victoza superior to Amylin rival COPENHAGEN (Reuters) - Denmark's Novo Nordisk, the world's biggest insulin producer, said on Monday a study had confirmed its diabetes drug Victoza provided greater reductions in blood sugar levels than rival drug Byetta from Amylin. Novo Nordisk said in a statement the study, presented at the 72nd Annual Scientific Sessions of the ADA in Philadelphia, showed more patients appeared to favor a drug given by injection over a drug which is given orally. The study also confirmed weight loss and cost-effectiveness in the use of Victoza, Novo Nordisk said. Reporting by Copenhagen Newsroom; Editing by Mark Potter